InflaRx N.V. (IFRX)
Automate Your Wheel Strategy on IFRX
With Tiblio's Option Bot, you can configure your own wheel strategy including IFRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IFRX
- Rev/Share 0.002
- Book/Share 1.113
- PB 0.6389
- Debt/Equity 0.01
- CurrentRatio 5.284
- ROIC -0.7518
- MktCap 47734488.844
- FreeCF/Share -0.7541
- PFCF -0.9998
- PE -1.0066
- Debt/Assets 0.0081
- DivYield 0
- ROE -0.6403
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | IFRX | Raymond James | Strong Buy | Outperform | -- | $2 | May 29, 2025 |
| Initiation | IFRX | Cantor Fitzgerald | -- | Overweight | -- | $10 | April 29, 2025 |
News
InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease
Published: May 28, 2025 by: Benzinga
Sentiment: Negative
InflaRx N.V. IFRX on Wednesday announced that the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase 3 trial for vilobelimab in pyoderma gangrenosum (PG) recommended that the trial be stopped due to futility.
Read More
InflaRx to Participate in Upcoming Investor Conferences
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
JENA, Germany, May 22, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in multiple investor conferences in June and July 2025.
Read More
InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
JENA, Germany, May 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its financial results for the three months ended March 31, 2025, and provided a business update.
Read More
InflaRx to Report First Quarter 2025 Results on May 7, 2025
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2025 financial and operating results on May 7, 2025, before the market opens. No conference call is planned.
Read More
InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Negative
InflaRx (IFRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Read More
InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
JENA, Germany, March 20, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its financial results for the year ended December 31, 2024, highlighting recent operational achievements and expected milestones for 2025.
Read More
InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
Published: February 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
JENA, Germany, Feb. 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced acceptance of all submitted abstracts, featuring the role of vilobelimab in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS), to be presented during the 2025 American Academy of Dermatology (AAD) Annual Meeting, March 7 - 11, in Orlando, FL.
Read More
InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
JENA, Germany, Feb. 18, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has completed its underwritten public offering of 8,250,000 ordinary shares of the Company at a public offering price of $2.00 per ordinary share and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 6,750,000 of the Company's ordinary shares.
Read More
InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
JENA, Germany, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today the pricing of its underwritten public offering of 8,250,000 ordinary shares of the Company at an offering price of $2.00 per ordinary share and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 6,750,000 of the Company's ordinary shares. The purchase price of each pre-funded warrant is equal to the price per share at which ordinary shares are being sold to the public in this offering, minus $0.001, which …
Read More
InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
JENA, Germany, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has commenced an underwritten public offering of ordinary shares of the Company, and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase the Company's ordinary shares. The purchase price of each pre-funded warrant will equal the price per share at which ordinary shares are being sold to the public in this offering, minus $0.001, which will be the exercise price of each pre-funded warrant. All ordinary shares and pre-funded …
Read More
About InflaRx N.V. (IFRX)
- IPO Date 2017-11-07
- Website https://www.inflarx.de
- Industry Biotechnology
- CEO Niels C. Riedemann
- Employees 74